.0001). Outpatient and other costs comprised 4-9% of the total cost increase. Similarly for patients, the majority of cost increases were due to hospital visits: 43% due to a 9-fold increase in hospitalization costs ($22 v $207; p < 0.0001), 0.25% due to a 20% increase in ER costs ($5 v $6; p = 0.35), and 38% due to a 5-fold increase in other hospital outpatient costs ($39 v $200; p < 0.0001). Outpatient and other costs comprised 5-7% of the total cost increase. CONCLUSIONS: Insurer and patient costs increase substantially following HCC diagnosis, primarily due to hospitalizations. Future therapies should demonstrate improved disease control to reduce this burden for insurers and patients. January 2002-December 2008 to identify patients diagnosed with CML (ICD-9 code 205.1x) and received ≥1 prescription of dasatinib or nilotinib. Patients were required to have continuous enrollment ≥1 month prior to and after the index date. The index date was defined as the first prescription for dasatinib or nilotinib. Patients were followed for up-to 6 months from the index date to the earliest of the termination of health care plan enrollment, or end of data availability. Negative binomial regression models were used to compare health care resource utilization between the two groups. Results were reported as unadjusted and adjusted incidence rate ratios (IRR). Health care costs were compared and reported as unadjusted and adjusted cost differences. These were estimated for each cost component using generalized linear models or two-part models. Multivariate regressions controlled for age, gender, and CML disease complexity. RESULTS: A total of 230 CML patients receiving a second-line TKI (186 dasatinib and 44 nilotinib) were studied. During the study period, dasatinib patients had significantly more medical visits (IRR = 1.32, p = .028). Dasatinib patients had 36% more hospital days but the difference was not statistically significant (IRR = 1.36, p = 0.664). Over the 6-month follow-up period, patients on dasatinib incurred $18,328 (p < .001) more in total medical services and $6,367 (p = 0.04) less in pharmacy costs, resulting in a higher net total health care cost of $12,039 (p = .035). The difference in medical costs was mainly explained by the difference of inpatient costs ($12,480; p = < .001) and outpatient costs ($5,035; p = .001). CONCLUSIONS: Among CML patients treated with a second-line TKIs, dasatinib patients incurred higher total health care costs and more frequent health care resource utilization than nilotinib patients.
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PCN48 NON-ADHERENCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IS ASSOCIATED WITH SHORT-AND LONG-TERM NEGATIVE IMPACTS ON HEALTH CARE RESOURCE UTILIZATION AND COSTS
Guerin A 1 , Bollu V 2 , Guo A 2 , Wu EQ 3 , Yu AP 3 , Sirulnik LA 2 , Griffin JD 4 1 Analysis Group, Ltee., Montreal, QC, Canada, 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3 Analysis Group, Inc., Boston, MA, USA, 4 Dana Farber Cancer Institute, Boston, MA, USA OBJECTIVES: To study health care resource utilization and costs associated with long-term non-adherence to imatinib in CML patients. METHODS: Two large administrative claims databases were combined (MarketScan and Ingenix Impact, January 2002-July 2008) to identify patients diagnosed with CML (ICD-9 code 205.1x). Patients with ≥2 imatinib prescriptions and continuous enrollment (≥6 months prior to and ≥1month post index date) were selected. Patients were followed for up to 3 years after the index date. A longitudinal retrospective open-cohort design was used to measure patients' adherence to imatinib repeatedly over time. Imatinib treatment periods were divided into 90-day intervals. Treatment intervals were categorized as adherent (MPR ≥85%) or non-adherent (MPR < 85%). Patients' health care utilization and costs were compared between adherent and non-adherent intervals. Multivariate regression models were used to compare rates of inpatient admissions, outpatient visits, and emergency room visits, controlling for clinical and demographic characteristics. Additional regression models including past cumulative MPR were used to assess the long-term impact of non-adherence. RESULTS: For the 1877 CML patients in the study, there were 6175 adherent and 3163 non-adherent intervals. Only 34% of patients were fully adherent throughout the observation period. During nonadherent intervals, patients incurred significantly more inpatient (IRR = 2.76, p < 0.001), ER (IRR = 1.25, p = 0.021), and outpatient (IRR = 1.09 p = 0.001) visits. Though non-adherence was associated with lower pharmacy cost ($3053 p < 0.001), this difference was outweighed by higher medical costs ($4531 p < 0.001), resulting in a net cost increase ($1477 (p < 0.001). Patients who were adherent throughout their observation period incurred an average cost of $11,759 per interval, compared to $13,773 for patients who were not always adherent. In patients who had not always been adherent (past cumulative MPR < 85%) an adherent interval cost $1,239 (p = .002) more, while another non-adherent interval cost $2122 (p < 0.001) more compared to an adherent interval in patients who had been adherent. CONCLU-SIONS: Imatinib non-adherence is associated with long-term negative economic consequences.
PCN49 COSTS TO MEDICARE OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH ALEMTUZUMAB
Lafeuille MH 1 , Vekeman F 2 , Kerrigan M 3 , Wang ST 4 , Duh MS 4 1 Groupe d'analyse, Ltée, Montreal, QC, Canada, 2 Analysis Group, Inc., Washington , DC, USA, 3 GlaxoSmithKline, Philadelphia, PA, USA, 4 Analysis Group, Inc., Boston, MA, USA OBJECTIVES: Alemtuzumab has been demonstrated to reduce the amount of malignant lymphocytes in patients with chronic lymphocytic leukemia (CLL). The current study aimed to quantify the incremental cost to Medicare of treating CLL patients with alemtuzumab. METHODS: Claims records (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) from the Medicare 5% national sample were analyzed. Patients with continuous enrollment for ≥3 months prior to their first observed claim with a CLL diagnosis, ≤2 malignancies, and ≥1 claim for alemtuzumab were included. A pre-post design was used to quantify the incremental costs associated with alemtuzumab by calculating health care costs within 6 months after alemtuzumab initiation relative to the 6-month period before alemtuzumab initiation. Mean monthly (per-patient per-month, PPPM) costs were calculated and were grouped by sites of care, service type, tests and procedures, treatment and drugs, and by adverse events. Statistical comparisons between the pre-and post-treatment periods were based on paired Student t-tests. RESULTS: A total of 81 CLL patients treated with alemtuzumab formed the study population. The mean age was 75.2 years and females represented 38.3%. Patients were observed for an average of 50 months and mean time between the first CLL diagnosis and initiation of alemtuzumab treatment was 36 months. After alemtuzumab initiation, mean total health care costs increased from $4,272 to $10,385 PPPM (P < 0.0001). Patients had a mean of 11.8 claims for alemtuzumab and the mean cost for alemtuzumab was $4,006 PPPM or 39% of total costs. PPPM costs associated with diagnostic codes for cytopenia, infection, and cardiac dysfunction were greater during the post-compared with the pre-alemtuzumab period (cytopenia: $1,658 vs. $4,114; infection: $107 vs. $841; cardiac dysfunction: $766 vs. $1,692; P < 0.05 for all). CONCLUSIONS: Amongst a cohort of Medicare fee-for-service patients with CLL, alemtuzumab was associated with a significant increase in health care costs in the 6 months after initiation of therapy.
PCN50 COSTS OF TREATMENT WITH ANGIOGENESIS INHIBITORS (AIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM A MEDICAL CHART REVIEW STUDY
Oh WK 1 , McDermott DF 2 , Duh MS 3 , Antràs L 3 , Chen K 3 , Sarda SP 3 , Luka A 3 , Whittemore S 3 , Ramamurthy P 3 , Neary MP 4 , Choueiri TK 5
